Clinicopathological analysis of CD44 and CD24 expression in invasive breast cancer

Jang,Min Hye; Kang,Hyun Jong; Jang,Ki Seok; Paik,Seung Sam; Kim,Wan Seop

doi:10.3892/ol.2016.4987

Clinicopathological analysis of CD44 and CD24 expression in invasive breast cancer

Authors:
- Min Hye Jang
- Hyun Jong Kang
- Ki Seok Jang
- Seung Sam Paik
- Wan Seop Kim
View Affiliations

Affiliations: Department of Pathology, Yeungnam University Hospital, Daegu 42415, Republic of Korea, Department of Surgery, Konkuk University Hospital, Chungju 27376, Republic of Korea, Department of Pathology, Hanyang University College of Medicine, Seoul 04763, Republic of Korea, Department of Pathology, Konkuk University School of Medicine, Seoul 05030, Republic of Korea
Published online on: August 10, 2016 https://doi.org/10.3892/ol.2016.4987
Pages: 2728-2733

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A subpopulation of breast cancer cells with cluster of differentiation (CD)44-positive and CD24‑negative expression has been reported to have stem cell properties and to have a higher tumorigenic capacity than other cells. However, the clinicopathological characteristics of this subpopulation are not fully understood. In this study, we aimed to identify the correlations between the expression of CD44 and CD24 and clinicopathological parameters and overall survival. We studied specimens from 262 patients with invasive breast cancer. Immunohistochemical staining for CD44 and CD24 was performed using tissue microarrays. The clinicopathological factors were evaluated from the patients' medical records. In correlation analysis, CD44 expression was significantly associated with human epidermal growth factor receptor 2 (HER2)‑negative status (P<0.001). Conversely, CD24 expression was significantly associated with HER2‑positive status (P<0.001). CD44 and CD24 expression did not demonstrate any correlation with the age, tumor size, axillary lymph node metastasis status, tumor stage, histological grade, estrogen receptor status and progesterone receptor status of patients. Upon survival analysis, there was no statistical difference in overall survival according to the expression of CD44 and CD24. The results from this study suggest that CD44 and CD24 are clinically significant markers associated with breast tumorigenesis, but not sufficient factors in determining the prognosis of invasive breast cancer.

View Figures

View References

1	Al-Hajj M, Becker MW, Wicha M, Weissman I and Clarke MF: Therapeutic implications of cancer stem cells. Curr Opin Genet Dev. 14:43–47. 2004. View Article : Google Scholar : PubMed/NCBI
2	Smalley M and Ashworth A: Stem cells and breast cancer: a field in transit. Nat Rev Cancer. 3:832–844. 2003. View Article : Google Scholar : PubMed/NCBI
3	Clarke MF and Fuller M: Stem cells and cancer: two faces of eve. Cell. 124:1111–1115. 2006. View Article : Google Scholar : PubMed/NCBI
4	Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
5	Ponta H, Sherman L and Herrlich PA: CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol. 4:33–45. 2003. View Article : Google Scholar : PubMed/NCBI
6	Hebbard L, Steffen A, Zawadzki V, Fieber C, Howells N, Moll J, Ponta H, Hofmann M and Sleeman J: CD44 expression and regulation during mammary gland development and function. J Cell Sci. 113:2619–2630. 2000.PubMed/NCBI
7	Aigner S, Sthoeger ZM, Fogel M, Weber E, Zarn J, Ruppert M, Zeller Y, Vestweber D, Stahel R, Sammar M and Altevogt P: CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells. Blood. 89:3385–3395. 1997.PubMed/NCBI
8	Kristiansen G, Winzer KJ, Mayordomo E, Bellach J, Schlüns K, Denkert C, Dahl E, Pilarsky C, Altevogt P, Guski H and Dietel M: CD24 expression is a new prognostic marker in breast cancer. Clin Cancer Res. 9:4906–4913. 2003.PubMed/NCBI
9	Elston CW and Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 19:403–410. 1991. View Article : Google Scholar : PubMed/NCBI
10	Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med. 134:907–922. 2010.PubMed/NCBI
11	Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, et al: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 31:3997–4013. 2013. View Article : Google Scholar : PubMed/NCBI
12	Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer, and cancer stem cells. Nature. 414:105–111. 2001. View Article : Google Scholar : PubMed/NCBI
13	Abraham BK, Fritz P, McClellan M, Hauptvogel P, Athelogou M and Brauch H: Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res. 11:1154–1159. 2005.PubMed/NCBI
14	Mylona E, Giannopoulou I, Fasomytakis E, Nomikos A, Magkou C, Bakarakos P and Nakopoulou L: The clinicopathologic and prognostic significance of CD44+/CD24(−/low) and CD44⁻/CD24⁺ tumor cells in invasive breast carcinomas. Hum Pathol. 39:1096–1102. 2008. View Article : Google Scholar : PubMed/NCBI
15	Lü X, Xu K, Lü H, Yin Y, Ma C, Liu Y, Li H and Suo Z: CD44(+)/CD24(−) cells are transit progenitors and do not determine the molecular subtypes and clinical parameters in breast carcinomas. Ultrastruct Pathol. 35:72–78. 2011. View Article : Google Scholar : PubMed/NCBI
16	Iida N and Bourguignon LY: New CD44 splice variants associated with human breast cancers. J Cell Physiol. 162:127–133. 1995. View Article : Google Scholar : PubMed/NCBI
17	Naor D, Sionov RV and Ish-Shalom D: CD44: Structure, function, and association with the malignant process. Adv Cancer Res. 71:241–319. 1997. View Article : Google Scholar : PubMed/NCBI
18	Henniker AJ: CD24. J Biol Regul Homeost Agents. 15:182–184. 2001.PubMed/NCBI
19	Fogel M, Friederichs J, Zeller Y, Husar M, Smirnov A, Roitman L, Altevogt P and Sthoeger ZM: CD24 is a marker for human breast carcinoma. Cancer Lett. 143:87–94. 1999. View Article : Google Scholar : PubMed/NCBI
20	Horiguchi K, Toi M, Horiguchi S, Sugimoto M, Naito Y, Hayashi Y, Ueno T, Ohno S, Funata N, Kuroi K, et al: Predictive value of CD24 and CD44 for neoadjuvant chemotherapy response and prognosis in primary breast cancer patients. J Med Dent Sci. 57:165–175. 2010.PubMed/NCBI
21	Bànkfalvi A, Terpe HJ, Breukelmann D, Bier B, Rempe D, Pschadka G, Krech R and Böcker W: Gains and losses of CD44 expression during breast carcinogenesis and tumour progression. Histopathology. 33:107–116. 1998. View Article : Google Scholar : PubMed/NCBI
22	Herrera-Gayol A and Jothy S: Adhesion proteins in the biology of breast cancer: contribution of CD44. Exp Mol Pathol. 66:149–156. 1999. View Article : Google Scholar : PubMed/NCBI
23	Lockhart M Sanchez, Hajos SE, Basilio FM, Mongini C and Alvarez E: Splice variant expression of CD44 in patients with breast and ovarian cancer. Oncol Rep. 8:145–151. 2001.PubMed/NCBI
24	Looi LM, Cheah PL, Zhao W, Ng MH and Yip CH: CD44 expression and axillary lymph node metastasis in infiltrating ductal carcinoma of the breast. Malays J Pathol. 28:83–86. 2006.PubMed/NCBI
25	Honeth G, Bendahl PO, Ringnér M, Saal LH, Gruvberger-Saal SK, Lövgren K, Grabau D, Fernö M, Borg A and Hegardt C: The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res. 10:R532008. View Article : Google Scholar : PubMed/NCBI
26	Baumann P, Cremers N, Kroese F, Orend G, Chiquet-Ehrismann R, Uede T, Yagita H and Sleeman JP: CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis. Cancer Res. 65:10783–10793. 2005. View Article : Google Scholar : PubMed/NCBI
27	Athanassiadou P, Grapsa D, Gonidi M, Athanassiadou AM, Tsipis A and Patsouris E: CD24 expression has a prognostic impact in breast carcinoma. Pathol Res Pract. 205:524–533. 2009. View Article : Google Scholar : PubMed/NCBI
28	Schindelmann S, Windisch J, Grundmann R, Kreienberg R, Zeillinger R and Deissler H: Expression profiling of mammary carcinoma cell lines: Correlation of in vitro invasiveness with expression of CD24. Tumour Biol. 23:139–145. 2002. View Article : Google Scholar : PubMed/NCBI